NCM
PCVX icon

NEXTBio Capital Management’s Vaxcyte PCVX Stock Holding History

NEXTBio Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.23M Buy
107,223
+12,000
+13% +$652K 2.87% 13
2026
Q1 		$5.53M Sell
95,223
-262
-0.3% -$14.2K 2.57% 15
2025
Q4 		$4.41M Buy
+95,485
New +$4.27M 2.58% 16

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

NEXTBio Capital Management's PCVX Position: Q2 2026 in Review

NEXTBio Capital Management increased its Vaxcyte (PCVX) stake by 13% in Q2 2026, buying an estimated $652K and bringing the position to 107,223 shares worth $6.23M. The position accounts for 2.87% of the portfolio, ranked #13.

NEXTBio Capital Management first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • NEXTBio Capital Management held 107,223 shares of Vaxcyte worth $6.23M as of Q2 2026.
  • NEXTBio Capital Management bought 12,000 Vaxcyte shares in Q2 2026, an estimated $652K.
  • Vaxcyte made up 2.87% of NEXTBio Capital Management's portfolio in Q2 2026, its #13 holding.
  • NEXTBio Capital Management first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.